Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
QLS5212 in Advanced Solid Tumors
NCT07467629Phase 1Recruiting
- Sponsor
- Qilu Pharmaceutical
- Start
- May 2026
- Primary completion
- Nov 2027
- Modality
- Monoclonal Antibodies, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of QLS5212 in solid tumor, sponsored by Qilu Pharmaceutical. Primary endpoints: Maximum Tolerated Dose up to 14 months, Dose-Limiting Toxicity at 21 days and 2 more. Started May 2026; status: recruiting.
02
Drugs
QLS5212
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT07467629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07467629.